Company / Operating Income
Marker Therapeutics, Inc. Operating Income History
FY2018-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$39.5M
FY2021
5-year range
-$39.5M / -$11.5M
FY2018-FY2021
Trend
-75.2%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$11M to -$39M over the past 3 years.
Based on SEC 10-K filings.
-$39M in FY2021.
Declined from -$11M to -$39M over the past 3 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2021, operating income decreased 75.2% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2021 | -$39.5M | -75.2% |
| FY2019 | -$22.5M | -96.2% |
| FY2018 | -$11.5M | - |
As of FY2021 · SEC 10-K · Updated Jun 28, 2026